Stuart A. Arbuckle, EVP, Chief Commercial Officer at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 21,790 shares at $210.05 ($4.6M) on 2021-02-18, disclosed to the SEC on 2021-02-19.
Seasonal sale ($4.6M) by EVP, Chief Commercial Officer — this insider has traded VRTX in February in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $211.75 | 6,240 | $1.3M | 28.6% |
| 2 | $210.05 | 1,022 | $215K | 4.7% |
| 3 | $210.05 | 1,022 | $215K | 4.7% |
| 4 | $211.77 | 3,940 | $834K | 18.1% |
| 5 | $211.77 | 3,940 | $834K | 18.1% |
| 6 | $212.49 | 2,763 |
| $587K |
| 12.7% |
| 7 | $212.49 | 2,763 | $587K | 12.7% |
| 8 | $213.26 | 100 | $21K | 0.5% |
| Total | $211.79 avg | 21,790 | $4.6M | 100% |
| Filing → |
| VRTX | SELL | 2024-02-23 | $3.0M | — | Filing → |
| VRTX | SELL | 2024-02-21 | $4.0M | — | Filing → |
| VRTX | SELL | 2024-02-13 | $3.6M | — | Filing → |